ASR Vermogensbeheer N.V. 13F: Cuts TMO Stake by $40M

ASR Vermogensbeheer N.V. has reduced its position in Thermo Fisher Scientific Inc. (NYSE: TMO) by 58,988 shares, leaving it with 34,721 shares valued at about $23.4 million, according to its latest Form 13F filing disclosed on October 16, 2026.

What Changed in ASR Vermogensbeheer's Thermo Fisher Position

ASR Vermogensbeheer cut its stake in Thermo Fisher by approximately 62.9%. This reduction came as the fund now holds a significantly smaller portion of the company compared to its previous 93,709 shares.

Other Institutional Activity in Thermo Fisher

Other institutional investors have also adjusted their positions in Thermo Fisher. Blackrock Inc. grew its holdings by 492,913 shares, ending with 30,919,632 shares worth approximately $21.3 billion. FMR, LLC increased its stake by 3,308,292 shares, bringing its total to 14,084,488 shares valued at around $9.7 billion. Meanwhile, Vanguard Capital Management LLC slightly reduced its position by 4,856 shares, now holding 24,276,316 shares valued at about $16.8 billion.

Thermo Fisher Scientific Inc. Stock Down 1.6%

Thermo Fisher Scientific shares recently traded around $685.18, which is above its 50-day moving average of $634.49 and 25.3% higher than its 200-day average of $546.79. However, the stock remains about 2.7% below its 52-week high of $704.00. The current share price is just below the consensus target mean price of $688.69 set by analysts.

Recent Earnings

Thermo Fisher reported trailing twelve-month revenue of approximately $46.34 billion, with a year-over-year revenue growth of 10.5%. Its net margin stands at 15.0%, and the next earnings report is scheduled for October 21, 2026.

Dividend

Thermo Fisher pays an annual dividend rate of $1.88, yielding about 0.27% with a payout ratio of 9.7%.

Insider Buying and Selling at Thermo Fisher Scientific Inc.

Recent insider selling included notable transactions by key executives. On August 19, Officer Lisa P. Britt sold 11,440 shares for about $7.0 million. CEO Marc N. Casper sold 20,000 shares on August 21, valued at approximately $12.6 million, and another 275 shares on August 24. Additionally, President Gianluca Pettiti sold 4,133 shares for around $2.5 million on August 31. These transactions occurred prior to the recent filing and reflect ongoing adjustments by insiders.

Analysts Set New Price Targets

Analysts continue to show confidence in Thermo Fisher. On October 13, Morgan Stanley maintained an 'Overweight' rating with a price target of $730. Prior to that, Barclays also maintained its 'Overweight' rating with a target of $750 on October 7. The consensus recommendation among 26 analysts is a 'Strong Buy' with a mean target price of $688.69.

About Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. provides a wide range of life sciences solutions, analytical instruments, and laboratory products. It operates in four segments, playing a key role in diagnostics and research internationally. ASR Vermogensbeheer's recent moves may reflect broader trends in the market or the company's current performance.

Bottom Line

Investors should keep an eye on Thermo Fisher's upcoming earnings report on October 21, 2026, for further insights into the company's performance. Note that ASR Vermogensbeheer's filing reflects its holdings as of the reporting period and may not represent its current position.